Gain Therapeutics (GANX) Net Margin (2020 - 2023)

Gain Therapeutics has reported Net Margin for 4 years, with the latest figure at 9310.11% in Q1 2023.

• On a quarterly basis, Net Margin fell 203854.0% year-over-year to 9310.11% in Q1 2023; TTM through Dec 2023 was 40878.89%, a 2832376.0% decrease from a year earlier, with the FY2023 full-year figure at 40878.89%, down 2832376.0% from the prior year.
• Net Margin was 9310.11% for Q1 2023 at Gain Therapeutics, down from 5347.33% in the prior quarter.
• The five-year high for Net Margin was 3988.53% in Q2 2021, with the low at 46506.87% in Q1 2021.
• Average Net Margin over 4 years is 13108.43%, with a median of 8755.7% recorded in 2020.
• The sharpest annual moves came in 2021 and 2022: Net Margin slumped 3775117 bps in 2021, then soared 3923530 bps in 2022.
• Over 4 years, Net Margin stood at 18116.65% in 2020, then jumped by 59 bps to 7452.17% in 2021, then climbed by 28 bps to 5347.33% in 2022, then plunged by 74 bps to 9310.11% in 2023.
• The last three Net Margin figures came in at 9310.11% (Q1 2023), 5347.33% (Q2 2022), and 7271.57% (Q1 2022), per Business Quant data.